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Abstract
The altered aggregation of proteins in non-native conformation is associated with endoplasmic
reticulum derangements, mitochondrial dysfunction and excessive production of reactive oxygen
species. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) is a rare hereditary systemic vasculopathy, caused by NOTCH3 mutations within the
receptor extracellular domain, that lead to abnormal accumulation of the mutated protein in the
vascular wall. NOTCH3 misfolding could cause free radicals increase also in CADASIL. Aim of the study
was to verify whether CADASIL patients have increased oxidative stress compared to unrelated
healthy controls. We enrolled 15 CADASIL patients and 16 gender- and age-matched healthy controls
with comparable cardiovascular risk factor. Blood and plasma reduced and total aminothiols
(homocysteine, cysteine, glutathione, cysteinylglycine) were measured by HPLC and plasma 3-
nitrotyrosine by ELISA. Only plasma reduced cysteine (Pr-Cys) and blood reduced glutathione (Br-GSH)
concentrations differed between groups: in CADASIL patients Br-GSH levels were higher (p = 0.019)
and Pr-Cys lower (p = 0.010) than in controls. No correlation was found between Br-GSH and Pr-Cys
either in CADASIL patients (rho 0.25, P=0.36) or in controls (rho -0.15, P=0.44). Conversely, 3-
nitrotyrosine values were similar in CADASIL and healthy subjects (p = 0.82). The high levels of
antioxidant molecules and low levels of oxidant mediators found in our CADASIL population might
either be expression of an effective protective action against free radical formation at an early stage
of clinical symptoms or they could suggest that oxidative stress is not directly involved in the
pathogenesis of CADASIL.
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Introduction
Perturbation of the oxidant/antioxidant balance
within the cells has been suggested to be involved in
the pathogenesis of several neurodegenerative
disorders such as stroke [1], Parkinson’s disease [2]
and Alzheimer’s disease [3]. These neurological
disorders are associated with the production of
abnormally aggregated proteins and belong to the
group of protein conformational diseases.
The altered aggregation of proteins in non-native
conformation is generally associated with
derangements of the endoplasmic reticulum and stress,
which leads to mitochondrial dysfunction and excessive
production of reactive oxygen species (ROS) [4]. When
the rate of free radical generation exceeds the capacity
of antioxidant defenses, oxidative stress ensues
causing extensive damage to DNA, proteins and lipids.
An increasing body of evidence suggests that
dysfunction of cell energy metabolism is an important
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factor in neurotoxicity mediated by nitric oxide (NO)
and that the intracellular content of thiols is crucial in
determining the sensitivity of cells to oxidative and
nitrosative stress [5]. The actions of NO can be either
direct, resulting from reactions between NO and
specific biological molecules, or indirect, resulting from
reactions of NO-derived reactive nitrogen species. For
instance, the reaction of NO with superoxide produces
the peroxynitrite anion and represents an important
pathway of NO reactivity [6]. Peroxynitrite is a powerful
oxidant and can nitrate aromatic amino acid residues
such as tyrosine to form nitrotyrosine.
Cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy
(CADASIL) is a rare hereditary systemic vasculopathy,
caused by mutations in the NOTCH3 gene encoding a
transmembrane receptor mainly expressed in vascular
smooth muscle cells (VSMC) in adult human tissue [7].
The notion of CADASIL as a systemic disease is
supported by the finding of diffuse structural small
vessel abnormalities not only in the brain, but also in
the skin, nerves, and muscles [7]. Furthermore altered
endothelium-dependent vasodilation in peripheral
resistance vessels has been previously documented
[8,9]. Within the extracellular domain of the receptor,
NOTCH3 mutations alter the number of cysteine
residues, leading to the abnormal accumulation of the
mutated protein in the vascular wall [10]. Misfolding of
NOTCH3 might thus cause an increase in ROS levels
also in CADASIL.
The aim of the present study was to verify whether
CADASIL patients have increased oxidative stress
compared to a control population of unrelated healthy
subjects by assessing plasma levels of 3-nytrotyrosine,
an index of nitration damage to proteins, and blood and




Fifteen subjects, aged 33 to 57 years, with a
diagnosis of CADASIL confirmed by the identification of
a mutation in the NOTCH3 gene were included in the
study. None of the patients had evidence of
autoimmune disorders, liver, or renal diseases. None
had experienced a cerebrovascular accident,
myocardial infarction or pulmonary embolism within
the 3 months preceding the study. None had been
taking antioxidant vitamin supplements for at least 2
months.
At enrolment, a detailed clinical history was collected
including concomitant treatments and cardiovascular
(CV) risk factors, defined according to current
guidelines: hypertension (systolic and diastolic blood
pressure ≥ 140 and 90 mmHg, respectively or on
antihypertensive medications) [11], hyperlipidemia
(LDL ≥160 mg/dL or current treatment with lipid-
lowering medications) [12], diabetes (documentation of
at least two measurements of fasting serum glucose ≥
126 mg/dL or on antidiabetic drugs) [13], smoking
habit. A neurological examination was performed and
disability rating scales (Bartel Index and Rankin scale)
were computed.
Sixteen unrelated subjects matched by age and
gender, with no history, signs or symptoms of
cerebrovascular and/or CV disease were enrolled as
controls.
The study was approved by the Niguarda Hospital
and Istituto Neurologico Carlo Besta Ethics Committee.
All subjects signed written consent forms to participate
in the study. The investigation conforms to the
principles outlined in the Declaration of Helsinki.
Biochemical assessment
After an overnight fast, an antecubital vein was
cannulated and blood was drawn into different pre-
chilled Vacutainer tubes for biochemical
determinations.
Blood and plasma reduced and total aminothiols
(homocysteine, cysteine [Cys], glutathione [GSH],
cysteinylglycine) were treated immediately after
sample collection and measured by HPLC with
fluorescence detection (ProStar, Varian, Surrey, UK)
according to methods previously described and
validated in our laboratory [14,15].
Plasma 3-nitrotyrosine was measured by using
sandwich ELISA kit (Hycult Biotech Inc., Plymouth
Meeting, PA) following the manufacturer’s instructions.
Serum glucose, γ-glutamyltransferase (GGT),
creatinine, AST, ALT, total cholesterol, HDL-cholesterol,
triglycerides, and C reactive protein (CRP) were
determined using standard laboratory methods, while
vitamin B12 and folates were measured by competitive
chemiluminescence immunoassay (Roche Diagnostic
GmbH, Mannheim, Germany). LDL-cholesterol was
calculated using the Friedewald’s method.
Statistical analysis
Continuous variables are presented as median and
interquartile ranges (I–III) or frequency (%). Between-
group differences were tested by Mann–Whitney U test
for continuous variables, chi-square test or Fisher’s
exact test when appropriate for categorical variables.
Spearman correlation coefficients were utilized to
examine relationships among the aminothiols.
Statistical analysis was carried out with the Statistical
Package for the Social Sciences (SPSS inc., Chicago, Ill.,
U.S.) release 17.0 for Windows. The level of
significance was set at P ≤ 0.05.
Oxidant/Antioxidant Balance in CADASIL
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Results
CADASIL population
Among the 15 enrolled CADASIL patients, a history of
migraine was present in 4 subjects (27%), 3 of whom
(20%) showed no other clinical manifestation. Previous
cerebrovascular events were recorded in 8 (53%)
patients: 3 (20%) had had transient ischemic attacks
and 5 (33%) a stroke. Four (27%) subjects were
asymptomatic mutation carriers. No subject had a
Rankin Scale value > 2 and a Barthel Index < 85, in
agreement with mild clinical impairment. NOTCH3 gene
mutations were distributed between exon 2 and 19,
with the greatest frequency in exon 4 (47%) and were
all missense mutations involving a Cys residue.
Redox balance inCADASIL patients and
controls
CV risk factor distribution was similar between
CADASIL patients and their gender- and age-matched
controls (Table 1). CADASIL patients showed lower
systolic blood pressure levels than controls (P <0.001).
Conversely serum concentrations of total cholesterol,
LDL, HDL, triglycerides, fasting glucose, creatinine,
AST, ALT, GGT, vitamin B12 and folate did not differ.
Among markers of oxidative stress (Table 2), only
plasma reduced Cys (Pr-Cys) values and blood reduced
GSH (Br-GSH) concentrations differed between groups.
Patients showed higher Br-GSH levels and lower Pr-Cys
compared to controls (Figure 1). No difference were
observed in 3-nitrotyrosine values between CADASIL
patients and healthy subjects.
We did not find any correlation between Br-GSH and
Pr-Cys in patients (rho 0.25, P=0.36), controls (rho
-0.21, P=0.49), or combined patients and controls (rho
-0.15, P=0.44).
Within the CADASIL group, no differences in the
aminothiol profile and nitrotyrosine levels were found
between patients with and those without a history of
cerebrovascular events (data not shown).
Discussion
Since oxidative stress is a prominent abnormality in
several neurodegenerative disorders, we investigated
the role of this biological mechanism in CADASIL
disease. The major novel findings of the present study
are that 3-nitrotyrosine, index of oxidative damage to
proteins, overlapped between CADASIL and control
subjects, whereas, among thiols, lower levels of the
oxidant marker Cys and higher concentrations of the
antioxidant molecule GSH were found in CADASIL
patients than in gender- and age-matched controls.
These results point to two different hypothesis: mildly
disabled CADASIL patients may exhibit enhanced
antioxidant protection or, alternatively, oxidative stress
may not represent a peculiar pathophysiologic
mechanism in this disease.
Aminothiols are key molecules in redox balance. Cys
and homocysteine share a pro-oxidant activity [16],
whereas cysteinilglycine and GSH exert antioxidant
protection.
The potential vascular toxicity of Cys has been
emphasized in several works. In vitro, Cys exhibits
auto-oxidation properties in the presence of metal ions,
with the ensuing generation of free radicals species
[16]. Cys was shown to produce, by inhibiting the
basally released endothelium-derived relaxing factor, a
dose-dependent contraction increase in the
endothelium [17]. Previous studies have reported
increased plasma total Cys levels in patients with
Table 1. Clinical characteristics of study population.
 Controls CADASIL p value
 (n=16) (n=15)  
Age, years 44 (39-55) 42 (39-49) 0.580
Male gender, n (%) 8 (50) 10 (67) 0.473
CV risk factors, (any) 11 (69) 6 (40) 0.156
Hypertension, n (%) 5 (31) 2 (13) 0.394
Dislipidemia, n (%) 4 (25) 4 (27) 1.000
Diabetes, n (%) 1 (6) 1 (7) 1.000
Smokers, n (%) 3 (19) 2 (13) 1.000
Laboratory findings
Total cholesterol, (mg/dL) 223 (202-250) 218 (200-243) 0.418
LDL-cholesterol (mg/dL) 140 (117-167) 147 (122-158) 0.800
HDL-cholesterol (mg/dL) 58 (44-73) 49 (42-63) 0.305
Triglycerides (mg/dL) 117 (68-143) 93 (66-134) 0.461
Fasting glucose, (mg/dL) 94 (81-100) 85 (76-94) 0.194
Creatinine (mg/dL) 0.80 (0.65-0.88) 0.89 (0.71-0.99) 0.135
AST (U/L) 20 (17-25) 21 (17-25) 0.861
ALT (U/L) 23 (13-36) 25 (19-31) 0.953
GGT (U/L) 19 (9-32) 23 (13-44) 0.358
Folate (ng/mL) 7.1 (5.3-10.3) 6.6 (4.5-10.2) 0.861
Vitamin B12, (pg/mL) 447 (358-581) 413 (344-580) 0.813
C-reactive protein (mg/dL) 0.1 (0.0-0.28) 0.1 (0.10-0.13) 0.804
Vital signs
Systolic blood pressure,
(mmHg) 132 (125-140) 115 (110-120) <0.001
Diastolic blood pressure
(mmHg) 80 (80-89) 75 (70-85) 0.098
Heart rate (bpm) 66 (60-74) 67 (64-72) 0.771
Drug therapy
ACE inhibitors, n (%) 1 (6) 2 (13) 0.600
Beta-blockers, n (%) 2 (12) 0 (0) 0.484
Calcium antagonists, n (%) 1 (6) 1 (7) 1.000
Statins, n (%) 0 (0) 3 (20) 0.101
Antiplatelets, n (%) 0 (0) 15 (100) <0.001
Data are presented as number (frequency %) or median (interquartile
range); p values are by chi-square test and Mann-Whitney test. CV,
cardiovascular; LDL, low-density lipoproteins; HDL, high-density
lipoproteins; AST, aspartate amino transferase; ALT, alanine amino
transferase; GGT, gamma-glutamyl transferase.
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myocardial infarction, cerebral infarction or peripheral
vascular disease [18]. However, the reduced form of
Cys is also one of the substrates for the synthesis of
GSH [19], which is produced from the precursors
gamma-glutamate, cysteine and glycine through the
enzymatic action of both glutamate-cysteine ligase and
GSH synthase. The low Pr-Cys concentrations found in
our CADASIL patients could thus be the result of an
increased metabolic rate of intracellular GSH
production (Figure 2): Br-GSH concentrations were in
fact higher in CADASIL compared to healthy subjects in
our study. Since the Cys pool substrate for Br-GSH
synthesis includes both extracellular (Pr-Cys) and
intracellular Cys, the lack of correlation between Br-
GSH and Pr-Cys observed in both patients and controls
does not allow to rule out this hypothesis.
GSH has several major physiological functions: it
maintains SH groups of proteins in a reduced state, it
participates in amino acid transport, it detoxifies
foreign compounds and enzymatically degenerates
endogenous peroxides, it forms bioactive molecules
and acts as a coenzyme in several enzymatic reactions
[20]. GSH is a free radical scavenger and a proton
donor for GSH peroxidase that is known to play a
neuroprotective role [21]. Reduced GSH levels have
been found in a number of neurodegenerative diseases
that present oxidative stress, as well as in the process
of normal aging [22].
Changes of GSH metabolism have been observed in
moderate and severe ischemic stroke [23]. Increased
activities of GSH peroxidase and GSH transferase are
the most typical changes, but an increase in GSH
reductase and GSH was also observed [24]. Ozkul et al.
reported high GSH concentrations with concomitantly
high malondialdehyde levels in patients with acute
ischemic stroke [25].
Table 2. Oxidant/antioxidant balance in controls
and in CADASIL patients.
 Controls (n=16)CADASIL (n=15) p value
Pt-Cys (µmol/mL) 244 (208-289) 265 (258-289) 0.406
Pr-Cys (µmol/mL) 12 (11-13) 10 (9-11) 0.010
Pt-CysGly (µmol/mL) 30 (21-37) 33 (28-39) 0.286
Pr Cys–Gly, (µmol/mL) 4.6 (3.3-5.3) 4.3 (2.8-5.1) 0.629
Pt-Hcy (µmol/mL) 8.0 (7.3-8.9) 9.0 (6.7-10.4) 0.423
Pr-Hcy (µmol/mL) 0.18 (0.17-0.20) 0.17 (0.15-0.32) 0.892
Pt-GSH (µmol/mL) 6.3 (4.7-8.6) 6.8 (5.3-7.5) 0.968
Pr-GSH (µmol/mL) 4.0 (1.9-4.9) 3.4 (2.1-5.4) 0.765
Bt-GSH (µmol/mL) 985 (851-1101) 1015 (980-1065) 0.316
Br-GSH (µmol/mL) 584 (527-709) 763 (675-870) 0.019
3-nitrotyrosine, (µmol/mL) 35 (5-66) 28 (16-45) 0.821
Data are presented as median (interquartile range); p values are by
Mann-Whitney test. P, plasma; t total; r reduced; B, blood, Cys, cysteine;
CysGly, cysteinylglycine; Hcy, homocysteine; GSH, glutathione.
Figure 1.  Reduced plasma Cys and blood GSH in controls and CADASIL patients.  Box plot of the
distribution of reduced plasma Cys and blood GSH concentrations in controls (empty box) and CADASIL patients
(dark box). The horizontal line in the middle of each box indicates the median; the top and bottom borders of the
box mark the 75th and 25th percentiles, respectively; and the whiskers represent the highest and lowest values that
are not outliers or extreme values.
doi: 10.1371/journal.pone.0067077.g001
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The GSH system has been supposed to play an
important role in brain tolerance to ischemia. The high
intracellular GSH levels found in our patients might
represent a defensive mechanism against the chronic
cerebral hypoperfusion that characterizes CADASIL
disease. Cerebrovascular dysfunction in addition to
microcirculatory rarefaction are, in fact, the earliest
consequences of pathogenic mutant NOTCH3
expression [7].
In contrast with other evidences, we did not find any
increase in pro-oxidant aminothiols and nitrotyrosine as
oxidative stress marker in CADASIL patients. Ragno et
al. observed changes in telomere length of peripheral
blood leukocytes, a condition that is often associated
with high levels of oxidative stress and chronic
inflammation [26]. Ferrer et al. reported a link between
vascular pathology and semicarbazide-sensitive amine
oxidase (SSAO) overexpression [27]. This enzyme,
which is selectively expressed in human brain blood
vessels, but not in other cellular components (e.g.,
neurons and glial cells), plays a role as mediator in
reactions involving H2O2 production [28]. Moreover,
Formichi et al. have reported an increase of oxidative
Figure 2.  Interplay between oxidative stress and aminothiols.  Cysteine is the substrate for the intracellular
synthesis of glutathione. Low plasma levels might result from increased influx across the cell membrane and
conseuently increased blood glutathione. At the intracellular level glutathione through the enzyme glutathione
peroxydase scavenges free radicals such as hydrogen peroxide and peroxynitrite, with a lower production of
nitrotyrosine as net effect. CBS, cystathionine-beta-synthase; GCL, glutamate-cysteine ligase; GS, glutathione
synthase; GSH, glutathione; GPx, glutathione peroxidase; H2O2, hydrogen peroxide; iNOS, inducible nitric oxide
synthase; MS, methionine synthase; SOD, superoxide dismutase; NO•, nitric oxide; NO2-, nitrite; O2-•, superoxide
anion.
doi: 10.1371/journal.pone.0067077.g002
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stress-induced apoptosis in peripheral blood leukocytes
and fibroblasts from CADASIL patients [29].
Conversely, our CADASIL patients and healthy
controls had similar levels of plasma 3-nitrotyrosine, a
sensitive marker of oxidative stress. This compound
results from the oxidative interaction between nitric
oxide and superoxide anion, that produces the highly
reactive peroxynitrite, a potent oxidizing agent.
Peroxynitrite initiates lipid peroxidation in biological
membranes, hydroxylation and nitration of aromatic
amino acid residues, and sulfhydryl oxidation of
proteins [30]. Although 3-nitrotyrosine has been
confirmed to be a sensitive indicator of peroxynitrite
generation in ischemic stroke and in
neurodegenerative disorders [31], the analysis of other
markers might instead reveal oxidative imbalance in
CADASIL patients.
Since NOTCH3 mutations cause ubiquitous
degeneration of vascular smooth muscle cells [7], we
studied oxidative stress markers at the systemic rather
than cerebral level. Previous studies in
neurodegenerative and cerebrovascular disorders
found evidence of increased oxidative stress changes
in peripheral blood samples [2,3]. Negative findings
from the peripheral circulation in our population cannot
definitely rule out the possibility that local vascular
redox imbalance may indeed be present in the small
vessels of the brain, but not be reflected by blood level
changes. Increased oxidative stress, as expressed by
immunoistochemical SSAO determination, has been
proven in autoptic brain tissue samples of CADASIL
patients, who died at an advanced stage of their
disease, comparable to patients with Alzeihmer’s
disease [27]. On the other hand, systemic vascular
abnormalities have been consistently observed in
CADASIL patients. Structural small vessels changes
have been documented in skin biopsy samples [7] and
endothelial function has been previously shown to be
altered in small peripheral resistance vessels in a
substantial proportion of CADASIL patients [8,9] and to
correlate with reduced intracranial vasoreactivity [32].
This notion suggests that vascular abnormalities could
indeed be reflected by systemic biochemical
alterations.
ROS are key signalling molecules in neurohumoral
mechanisms involved in blood pressure regulation,
volume homeostasis, baroreflex function and
sympathetic activity [33,34]. Inhibition of ROS-
producing enzymes, antioxidants and ROS scavengers
lower blood pressure whereas pro-oxidants increase,
and free radicals have been causally associated with
hypertension in animal models. Oxidative stress in the
central nervous system is implicated in the neuro-
dysregulation associated with some forms of
hypertension. Our CADASIL patients showed instead
significantly lower blood pressure values than controls,
consistently with previous reports [35]. Relative
hypotension in these patients is postulated to derive
from functional failure of brain structures and
connections controlling circadian blood pressure
variations, secondary to white matter damage.
Conversely, at the relatively early stage of clinical
presentation in our series, it is also possible that the
increased antioxidant response might be a contributory
mechanism to hypotension, since at low concentrations
oxidants act as signaling molecules for vascular tone
regulation [1].
Some limitations of our study should be considered.
The sample was relatively small, as it commonly
occurs in similar studies on patients affected by such a
rare disease. An imbalance in drug treatment was also
observed: 80% of CADASIL patients and none of
controls were taking aspirin and 20% statins, drugs
which are known to have antioxidant properties [36,37]
and might have damped deleterious oxidative stress
signals.
We did not measure the activity of enzymes involved
in GSH metabolism. However we evaluated the direct
product of their action, the intracellular GSH
concentration, so we discuss the net effect of possible
changes in enzyme activities.
In conclusion, the high levels of antioxidant
molecules and low or similar levels of oxidant
mediators found in our CADASIL population as
compared with control subjects point to two possible
hypotheses. These findings might be the expression of
an effective protective action against free radical
formation at an early stage of clinical symptoms.
Alternatively, our results may also support the
hypothesis that oxidative stress is not directly involved
in the pathogenesis of CADASIL and that antioxidant
changes may be related to other biological
mechanisms.
Further evaluation of multiple oxidative stress
markers and endogenous antioxidant capacity in a
larger population of CADASIL patients is warranted.
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